Patents Assigned to VNV NEWCO INC.
  • Endogenous Gag-based capsids and uses thereof
    Patent number: 11505578
    Abstract: Nucleic acids encoding endogenous Gag peptides can be isolated from various organisms. Nucleic acids encoding various endogenous Gag polypeptides can be isolated from human DNA. The nucleic acids can be used to express endogenous Gag polypeptides that can be assembled into capsids. Endogenous Gag polypeptides and capsids can be used package cargo and/or deliver it to cells, for example, to package and/or deliver a nucleic acid molecule for use in gene editing, such as a component involved in a CRISPR-Cas system.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: November 22, 2022
    Assignee: VNV NEWCO INC.
    Inventors: Colin Malone, Ian Peikon, Zachary Gilbert, Andrey Pisarev, Adam Fraites, Jessica Crisp
  • Endogenous Gag-based capsids and uses thereof
    Patent number: 11447527
    Abstract: Disclosed herein, in certain embodiments, are recombinant Arc and endogenous Gag polypeptides, and methods of using recombinant Arc and endogenous Gag polypeptides.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: September 20, 2022
    Assignee: VNV NEWCO INC.
    Inventors: Colin Malone, Ian Peikon, Zachary Gilbert, Andrey Pisarev, Adam Fraites, Jessica Crisp
  • Vaccine compositions comprising endogenous Gag polypeptides
    Patent number: 11129892
    Abstract: Described herein is a composition comprising: 1) an ARC polypeptide or an endogenous gag (endo-gag) polypeptide; 2) a pathogen-associated antigen; and 3) an adjuvant. Also described herein are vaccines and methods of vaccination using compositions comprising: 1) an ARC polypeptide or an endogenous gag (endo-gag) polypeptide; 2) a pathogen-associated antigen; and 3) an adjuvant.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: September 28, 2021
    Assignee: VNV NEWCO INC.
    Inventors: Zachary Gilbert, Colin Malone